173 related articles for article (PubMed ID: 32645898)
1. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.
McGuire A; Casey MC; Waldron RM; Heneghan H; Kalinina O; Holian E; McDermott A; Lowery AJ; Newell J; Dwyer RM; Miller N; Keane M; Brown JAL; Kerin MJ
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645898
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-326 could serve as a predictive biomarker for response to neoadjuvant chemotherapy in locally advanced cervical cancer.
Zou K; Yang E; Cui T; Li Z
Front Oncol; 2022; 12():1036710. PubMed ID: 36439477
[TBL] [Abstract][Full Text] [Related]
3. Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer.
Todorova VK; Byrum SD; Gies AJ; Haynie C; Smith H; Reyna NS; Makhoul I
Curr Oncol; 2022 Jan; 29(2):613-630. PubMed ID: 35200555
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
[TBL] [Abstract][Full Text] [Related]
5. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
7. Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
Ryspayeva D; Halytskiy V; Kobyliak N; Dosenko I; Fedosov A; Inomistova M; Drevytska T; Gurianov V; Sulaieva O
Discov Oncol; 2022 Jun; 13(1):43. PubMed ID: 35668332
[TBL] [Abstract][Full Text] [Related]
8. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Chatterjee D; Bal A; Das A; Singh G
Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
[TBL] [Abstract][Full Text] [Related]
9. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.
Chintamani ; Singh JP; Mittal MK; Saxena S; Bansal A; Bhatia A; Kulshreshtha P
World J Surg Oncol; 2005 Sep; 3():61. PubMed ID: 16164742
[TBL] [Abstract][Full Text] [Related]
10. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
[TBL] [Abstract][Full Text] [Related]
11. The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Van Berckelaer C; Vermeiren I; Vercauteren L; Rypens C; Oner G; Trinh XB; Tjalma WAA; Broeckx G; Charafe-Jauffret E; Van Laere S; Bertucci F; Colpaert C; van Dam PA
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572883
[TBL] [Abstract][Full Text] [Related]
12. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
[TBL] [Abstract][Full Text] [Related]
13. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
14. Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer.
Casey MC; Sweeney KJ; Brown JA; Kerin MJ
Int J Cancer; 2016 Jul; 139(1):12-22. PubMed ID: 26756433
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with MRI monitoring for breast cancer.
Dave RV; Millican-Slater R; Dodwell D; Horgan K; Sharma N
Br J Surg; 2017 Aug; 104(9):1177-1187. PubMed ID: 28657689
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant induction chemotherapy.
Schwartz G
Minerva Ginecol; 2005 Jun; 57(3):327-48. PubMed ID: 16166939
[TBL] [Abstract][Full Text] [Related]
19. Early changes of platelet‑lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer.
Dan J; Tan J; Huang J; Yuan Z; Guo Y
Mol Clin Oncol; 2023 Nov; 19(5):90. PubMed ID: 37854328
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Xiong Y; Liang LZ; Cao LP; Min Z; Liu JH
Gynecol Oncol; 2011 Oct; 123(1):99-104. PubMed ID: 21741694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
